Introduction {#s1}
============

Mutations in the metabolic proteins IDH1 and IDH2 are associated with gliomas, acute myeloid leukemias, chondrosarcomas, intrahepatic cholangiocarcinomas, lymphomas, melanomas and colon, thyroid and prostate cancers (for review, see [@bib8]). Previous work has shown that these mutations change the specificity of the reaction catalyzed by IDH proteins; instead of producing α-ketoglutarate from isocitrate, they produce 2-hydroxyglutarate (2HG), a metabolite that can have oncogenic effects ([@bib8]; [@bib12]; [@bib16]; [@bib18]; [@bib19]). Lu and colleagues expand upon this work to identify a potential mechanism for how 2HG can effect major changes in cell behavior. They present evidence that 2HG interferes with global demethylation that is required for progenitor cells to complete terminal differentiation. Transfection of 3T3-L1 cells with the mutant forms of *IDH1* and *IDH2* that produce 2HG lead to an increase in global methylation levels and prevented normal in vitro differentiation into adipocytes. The 2HG-sensitive histone demethylase KDM4C appeared to be required for this process, as knockdown of KDM4C recapitulated the phenotype of 2HG production. Examination of glioma samples showed a correlation between *IDH* mutation status and level of overall methylation ([@bib11]). Taken together, Lu and colleagues' findings help explain how mutations in IDH1 and IDH2 potentially interface with cancer development and progression.

In Figure 1B, Lu and colleagues examined the effects of mutations in *IDH1* and *IDH2* on global levels of methylation by transfecting mutant and wild type forms of the genes into 293T cells and using Western blot to assess the levels of various methylation markers. They also confirmed that introduction of the mutated forms of *IDH1* and *IDH2* correlated with increased intracellular levels of the oncometabolite 2HG. Their findings suggest that mutations in *IDH1* and *IDH2* correlate with increased levels of many methylation markers, and this key finding is replicated in Protocol 1.

In order to understand the effects of hypermethylation more fully, Lu and colleagues turned to an in vitro model of differentiation; when treated with appropriate signals, 3T3-L1 cells undergo epigenetic changes required for them to differentiation into adipocytes. In Figure 2A and B, they transfect undifferentiated 3T3-L1 cells with the wild type and mutant forms of IDH2 and assess the cells' ability to differentiate into adipocytes, as determined by staining for lipid droplets with Oil-Red-O. While differentiated 3T3-L1 cells transfected with vector only or wild type *IDH2* showed robust Oil-Red-O staining, cells transfected with mutant *IDH2* did not, indicating a block in differentiation. qRT-PCR confirmed that cells transfected with mutant *IDH* variants did not express high levels of known adipocyte markers (Figure 2D). This key finding will be replicated in Protocol 2.

Lu and colleagues identified a histone demethylase, *KDM4C*, expressed as 3T3-L1 differentiation progressed, that appeared to be sensitive to 2HG. In Figure 4D, they use siRNAs to knock down levels of *KDM4C* in differentiating 3T3-L1 cells. Western blot analysis and Oil-Red-O staining confirmed that loss of KDM4C increased global methylation levels and inhibited differentiation. This key finding will be replicated in Protocol 3.

Several aspects of Lu's findings have been corroborated by other work. Multiple groups have demonstrated that perturbations in IDH proteins alter methylation levels; overexpression of the *IDH1*^R132H^ allele in human tumor cells lines increased global histone methylation levels ([@bib3]), exogenous *IDH2*^R140Q^ increased methylation levels in erythroleukemia progenitor cells ([@bib7]) and an immortalized astrocyte cell line expressing *IDH1*^R132H^ also demonstrated increased levels of methylation ([@bib14]). Members of the Thompson lab (authors of this study) have confirmed that expression of mutant variants of IDH proteins in 3T3-L1 cells blocked differentiation into adipocytes ([@bib10]; [@bib17]). Sasaki and colleagues have shown that mutant *IDH1* expression increased levels of methylation in mice ([@bib13]), while Akbay and colleagues published a similar observation for mutant forms of *IDH2* ([@bib1]). This effect may even hold true for human patients, as there is a marked increase in H3K9me3 levels associated with *IDH* mutations in oligodendromas and high grade astrocytomas ([@bib15]).

Materials and methods {#s2}
=====================

Unless otherwise noted, all protocol information was derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (\*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (\#) indicates information provided by the replicating lab.

Protocol 1: Assessing the methylation status and 2HG production of 293T cells transfected with mutant forms of IDH1 and IDH2 {#s2-1}
----------------------------------------------------------------------------------------------------------------------------

This protocol describes how to transfect 293T cells with wild-type and mutant forms of IDH1 and IDH2 and assess levels of global methylation and 2HG production, as seen in Figure 1B and Supplemental Figure 1.

### Sampling {#s2-1-1}

-   Experiment will be repeated a total of 6 times for a minimum power of 80%. The metabolite data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.See \"power alculations\' for details.The metabolite data displayed in the bottom of Figure 1B were derived from Figure 3B of Figueroa and colleagues ([@bib6]).

-   Each experiment consists of five cohorts:Cohort 1: 293T cells transfected with vector onlyCohort 2: 293T cells transfected with wild-type *IDH1*Cohort 3: 293T cells transfected with *IDH1*^R132H^Cohort 4: 293T cells transfected with wild type *IDH2*Cohort 5: 293T cells transfected with *IDH2*^R172K^

-   Each cohort is then examined for methylation status by Western blot and levels of 2HG production by GC-MS.

### Materials and reagents {#s2-1-2}

  ------------------------------------------------------------------------------------------------------------------------------------------
  Reagent                               Type                   Manufacturer                Catalog \#    Comments
  ------------------------------------- ---------------------- --------------------------- ------------- -----------------------------------
  10 cm tissue culture dishes           Labware                Thermo Scientific           130182        Original unspecified

  Bradford Assay Kit                    Reporter assay         Bio-Rad                     500-0201EDU   Original unspecified

  DMEM                                  Cell culture           Corning                     15013 CV      Replaces original from Invitrogen

  Endo-free plasmid maxiprep kit        Kit                    Qiagen                      12362         Original unspecified

  Fetal bovine serum (FBS)              Cell culture           CellGro                     10437-028     Original cat \# unspecified

  293T cells                            Cell line              ATCC                        CRL-3216      Original source unspecified

  HRP-conjugated donkey\                Antibody               GE Healthcare               NA934V        
  anti-rabbit secondary                                                                                  

  HRP-conjugated sheep\                 Antibody               GE Healthcare               NA931V        
  anti-mouse secondary                                                                                   

  *IDH1* ORF clone                      Nucleic acid           OriGene                     RC210582      Replaces ATCC plasmid\
                                                                                                         in pCMV-Sport6

  *IDH1*^R132H^ ORF clone               Nucleic acid           OriGene                     RC400096      Original generated\
                                                                                                         by authors

  *IDH2* ORF clone                      Nucleic acid           OriGene                     RC201152      Replaces Invitrogen\
                                                                                                         plasmid in pOTB7

  *IDH2*^R172K^ ORF clone               Nucleic acid           OriGene                     RC400103      Original generated\
                                                                                                         by authors

  Mouse IgG1 monoclonal\                Antibody               Abcam                       Ab55271       
  anti-IDH2                                                                                              

  Nitrocellulose\                       Western blot reagent   Life Technologies           LC2006        Original source unspecified
  membrane                                                                                               

  Nonfat milk                           Western blot reagent   Carnation                                 Original source unspecified

  NuPAGE 4-12% precast\                 Western blot reagent   Invitrogen                  WG1401BOX     Original source unspecified
  gradient gel                                                                                           

  Pierce™ ECL Plus\                     Western blot reagent   Life Technologies           32132         Original unspecified
  Western Blotting Substrate                                                                             

  pLPC vector plasmid\                  Nucleic acid           Addgene                     18741         Original source unspecified
  (pLPC H-Ras V12)                                                                                       

  Ponceau stain                         Chemical               SIGMA                       P7170-1L      Original unspecified

  Protease Inhibitor\                   Inhibitor              Sigma-Aldrich               P8340         Original unspecified
  Cocktail,                                                                                              

  Rabbit IgG monoclonal\                Antibody               Cell Signaling Technology   4499          
  anti-H3                                                                                                

  Rabbit monoclonal\                    Antibody               Millipore                   17-614        
  anti-H3K4me3                                                                                           

  Rabbit polyclonal\                    Antibody               Abcam                       Ab9050        
  anti-H3K36me3                                                                                          

  Rabbit polyclonal\                    Antibody               Cell Signaling Technology   9757          
  anti-H3K79me2                                                                                          

  Rabbit polyclonal\                    Antibody               Cell Signaling Technology   9753          
  anti-H3K9me2                                                                                           

  Rabbit polyclonal\                    Antibody               Abcam                       Ab8898        
  anti-H3K9me3                                                                                           

  Rabbit polyclonal\                    Antibody               ProteinTech                 12332-1-AP    
  anti-IDH1                                                                                              

  TBS + Tween 20                        Buffer                 Fisher Scientific           BP-2471-1     Original source unspecified

  XCell II blot module                  Instrument             Life Technologies           EI9051        Original unspecified

  Acetonitrile, HPLC\                   Chemical               Spectrum                    HP412         Original source unspecified
  grade                                                                                                  

  Chloroform                            Chemical               Fisher                      C606-4        Original unspecified

  D-alpha-hydroxyglutaric\              Chemical               Santa Cruz Biotechnology    Sc-227739     Replaces original from Sigma
  acid disodium salt (2HG)                                                                               

  Methanol, HPLC grade                  Chemical               MP                          300141        Original source unspecified

  N-methyl-N-tert-butyldimethylsilyl\   Chemical               Soltec Ventures             GC102         Replaces original\
  trifluoroacetamide (MTBSTFA)                                                                           from Regis

  Norvaline                             Chemical               Sigma                       N7627         Original unspecified

  Protein Concentration\                Reporter assay         Bio-Rad                     500-0205      Original unspecified
  Assay; Quick Start\                                                                                    
  Bradford Assay                                                                                         

  Lipofectamine 2000                    Cell culture           Life Technologies           11668027      Original cat \# unspecified
  ------------------------------------------------------------------------------------------------------------------------------------------

### Procedure {#s2-1-3}

Note: 293T cells are maintained in DMEM with 10% FBS at 37°C/5% CO~2 ~All cells will be sent for STR profiling and mycoplasma testing.

-   Using the pLPC backbone and the OriGene ORF clones, clone in the sequences for wild-type *IDH1*, wild-type *IDH2, IDH1*^R132H^ or *IDH2*^R172K^ to generate the following vectors:pLPC-*IDH1*pLPC-*IDH2*pLPC-*IDH1*^R132H^pLPC-*IDH2*^R172K^

-   Prep each vector using an endo-free maxiprep kit according to the manufacturer's instructions.

-   Confirm plasmid identity by sequencing insert and vector integrity by agarose gel electrophoresis.Note; OriGene ORF clones are shipped with sequencing primers.

-   Plate 293T cells in ^\#^10 cm tissue culture dishes and let adhere overnight.Plate two plates; one will be harvested for Western blot (Step 3), the other for metabolite analysis (Step 4).

-   Transfect 293T cells with appropriate plasmids with Lipofectamine 2000 according to the manufacturer's instructions.Note: Prepare separate transfection mixtures for each replicate, then use the same mixture for all plates within that replicate; do not use a single large volume for transfection mixture for all replicates.pLPC (empty vector)pLPC-*IDH1*pLPC-*IDH2*pLPC-*IDH1*^R132H^pLPC-*IDH2*^R172K^Incubate for 3 days.At this point, the matched plates for each replicate will be harvested; one plate for Western blot analysis (Step 6), the matched plate for GC-MS analysis (Step 7).Note; from this point forward, the analysis of each replicate must be conducted separately and independently from the other replicates. For example, each replicate should be run on its own gels.

-   Western blot analysis of methylation status:Acid extraction of histones:Lyse cells in hypotonic lysis buffer for 1.Hypotonic lysis buffer: 10mM HEPES, 10mM KCl, 1.5mM MgCl~2~, 0.5mM DTT, ^\#^protease inhibitor cocktailAdd H~2~SO~4~ to 0.2N and incubate at 4°C overnight with rotation.^\#^Centrifuge samples at 6,500x*g* for 10min at 4°C to pellet debris.Precipitate proteins with 33% TCA.Wash with acetone.Resuspend in de-ionized water.^\*\#^Quantify protein concentration using a Bradford Assay.^\#^Load \~ 50 µg of protein per well and separate proteins on a 10% NuPAGE 4-12% gradient gel.^\#^Transfer to nitrocellulose membrane using an XCell II blot module at 25 V for 1-2 hr (start at 100 mA per gel).\*Perform a Ponceau stain and image to confirm transfer of proteins.Wash out Ponceau.Block membrane for ^\#^1 hr in 5% non-fat milk in PBS with 0.5% Tween-20.Incubate with primary antibodies ^\#^diluted in TBST + 1% nonfat milk at 4°C overnight. ^\*^Use the manufacturer's recommended dilution.Anti-IDH1Anti-IDH2Anti-H3K4me3Anti-H3K9me2Anti-H3K9me3Anti-H3K36me3Anti-H3K79me2Anti-H3 (loading control)^\#^Each antibody will have its own gel run. Membranes will not be stripped and reprobed.Wash membrane ^\#^twice with TBST for a total of 20 min.Incubate with HRP-conjugated secondary antibodies ^\#^diluted in TBST for 1 hr at room temperature. ^\#\*^Use manufacturer recommended dilutions.Wash three times with TBST.Detect signal ^\#^using ECL plus according to the manufacturer's instructions.Quantify band intensities with ImageJ.Normalize methylation band intensities to total H3.Divide normalized band intensities by the vector control band intensity.

-   Gas chromatography-mass spectrometry analysis of 2HG levels. Note; the data in the original paper and the methodology are derived from Figueroa and colleagues ([@bib6]).Gently remove culture medium from cells 3 days after transfection, ^\#^wash cells quickly three times with 2 ml ice-cold PBS, and add ^\#^0.5 ml ice-cold 80% methanol containing 20 µM L-norvaline per well of a 6-well plate to the cells.^\#^Quantify protein concentration using the ^\#^Bio-Rad Quick Start Bradford Assay.Incubate 20 min at -80°C.Centrifuge at 14000x*g* for 20 min at 4°C.^\#^Counter-extract samples with chloroform to remove nonpolar metabolites.Collect supernatant and dry using a ^\#^MiVac.Redissolve dried extracts in ^\#^60 µL of a 1:1 mixture of acetonitrile and N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide (MTBSTFA).Heat the samples for 75 min at 70°C.GC-MS analysis:^\#^A Shimadzu QP2010 Plus GC-MS is programmed with an injection temperature of 250°C, injection split ratio 1/10, with injection volume 0.3-1 µl. GC oven temperature starts at 130°C for 4 min, rising to 243°C at 6°C/min and to 280°C at 60°C/min with a final hold at this temperature for 2 min. GC flow rate with helium carrier gas was 50 cm/s. The GC column used is a 15 m x 0.25 mm x 0.25 µm Rxi-5ms (Restek). GC-MS interface temperature is 300°C and (electron impact) ion source temperature is 200°C, with 70 V/ 70 µA ionization voltage/ current. The mass spectrometer is set to scan m/z range 150-600, with \~1 kV detector sensitivity (modified as necessary).^\*\#^In parallel to the sample, run a standard curve of known amounts of 2HG.Confirm and ^\*\#^quantify 2HG metabolite peak using standard curve.Analyze and ^\*\#^quantify 2HG and glutamate signal (identified by elution time and mass fragment pattern) intensities by integration of peak areas.

-   Repeat independently from Step 4 onwards an additional five times.

### Deliverables {#s2-1-4}

-   Data to be collected:Sequence files and agarose gel images confirming vector identityFull gel images of western blots with ladder (as seen in Figure 1B)Images of Ponceau stained membranesQuantification of band intensities (as seen in Supplemental Figure 1A)GC-MS dataQuantification of signal intensities of 2HG and glutamate (as seen in Figure 1B)

### Confirmatory analysis plan {#s2-1-5}

-   Statistical Analysis of the Replication Data: Note: At the time of analysis we will calculate Pearson's *r* to check for correlation between the six dependent variables, normalized intensities measured for each of the histone lysine methylations, for the Western blot data. We will also perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the Western blot data and 2HG/glutamate ratios. We will also perform Levene's test to assess homoscedasticity. If the data appear skewed we will perform a log transformation in order to proceed with the proposed statistical analysis. If the log transformation does not result in similar variance across groups, we will perform the equivalent non-parametric test listed in Power Calculations for this protocol.Western blot:MANOVA (six dependent variables are the normalized intensities for each of the histone lysine methylations; four independent variables are the IDH1 and IDH2 variants (all normalized to vector) with the following planned comparisons using Bonferroni's correction:Wild-type IDH1 compared to IDH1^R132H^, for H3K9me2.Wild-type IDH2 compared to IDH2^R172K^, for H3K9me2.2HG/glutamate ratios:One-way ANOVA (one dependent variable is the 2HG/glutamate ratio; four independent variables are the IDH1 and IDH2 variants) with the following planned comparisons using Bonferroni's correction:IDH1^WT^ compared to IDH1^R132H^IDH2^WT^ compared to IDH2^R172K^

-   Meta-analysis of original and replication attempt effect sizes:For Western blot:The replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.For 2HG/glutamate ratios:The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the representative image, as a single point on the same plot for comparison.

-   Additional exploratory analysis:Correlation analysis (Pearson's *r*) of each of the six relative histone methylation levels to 2HG/glutamate levels using Bonferroni 's correction (as seen in Supplemental Figure 1B).

### Known differences from the original study {#s2-1-6}

-   The replication attempt will quantify total amounts of 2HG in addition to the ratio of 2HG to glutamate.

-   Aspects of the Western blot protocol are provided by the replicating lab; complete details of the original protocol were unavailable.

### Provisions for quality control {#s2-1-7}

All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/vfsbo/>).

-   Sequence files and agarose gel images confirming vector identity and integrity

-   Ponceau stains confirming protein transfer to membranes

-   STR profiling and mycoplasma testing results

Protocol 2: Examining the effects of mutations in IDH2 on differentiation of 3T3-L1 cells {#s2-2}
-----------------------------------------------------------------------------------------

This protocol describes how to induce the differentiation of 3T3-L1 cells into adipocytes, which involves extensive chromatin remodeling, after transfection with wild type and mutant forms of *IDH2* and assess the level of differentiation by Oil-Red-O staining, as seen in Figure 2A and B, and adipocyte marker expression, as seen in Figure 2D.

### Sampling {#s2-2-1}

-   This experiment will use 5 biological replicates for a minimum power of 80%. The metabolite data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.See Power Calculations for details.

-   Each experiment will consist of three cohorts:Cohort 1: 3T3-L1 cells transduced with vectorCohort 2: 3T3-L1 cells transduced with wild-type *IDH2*Cohort 3: 3T3-L1 cells transduced with *IDH2*^R172K^

-   Each cohort will have 5 plates per biological replicate:One plate will be used to assess IDH2 expression by Western blot.The second plate will be used to assess intracellular levels of 2HG.The third plate will be assessed for adipogenesis by Oil-Red-O staining.The fourth and fifth plates will have mRNA harvested for qRT-PCR analysis.

### Materials and reagents {#s2-2-2}

  Reagent                                                   Type                   Manufacturer         Catalog \#        Comments
  --------------------------------------------------------- ---------------------- -------------------- ----------------- -----------------------------------
  Isobutylmethylxanthine                                    Inhibitor              Sigma                I5879             Original cat\# unspecified
  Dexamethasone                                             Chemical               Sigma                D4902             Original cat\# unspecified
  Insulin                                                   Growth factor          Sigma                I3536             Original cat\# unspecified
  Troglitazone                                              Chemical               Sigma                T2573             Original cat\# unspecified
  pCL-Eco helper plasmid                                    Nucleic acid           Addgene              12371             Original source unspecified
  293T cells                                                Cell line              ATCC                 CRL-3216          Original source unspecified
  3T3-L1 cells                                              Cell line              ATCC                 CL-173            Original source unspecified
  Puromycin                                                 Chemical               Life Technologies    A11138-02         Original unspecified
  RIPA buffer                                               Cell culture           Millipore            20188             Original source unspecified
  Nitrocellulose membrane                                   Western blot reagent   Life Technologies    LC2006            Original source unspecified
  Ponceau stain                                             Chemical               Sigma                P7170             Original source unspecified
  Rabbit polyclonal anti-IDH1                               Antibody               ProteinTech          12332-1-AP        
  Mouse IgG1 monoclonal anti-IDH2                           Antibody               Abcam                Ab55271           
  HRP-conjugated donkey anti-rabbit secondary               Antibody               GE Healthcare        NA934V            
  HRP-conjugated sheep anti-mouse secondary                 Antibody               GE Healthcare        NA931V            
  Oil-Red-O                                                 Chemical               Sigma                O1391             Original source unspecified
  paraformaldehyde                                          Chemical               Tousimis             1008A             Original source unspecified
  6-well tissue culture plates                              Labware                Sarstedt             83.1839           Original unspecified
  XtremeGene HP reagent                                     Cell culture           Roche                06366244001       Original unspecified
  DMEM                                                      Cell culture           Corning              15013 CV          Replaces original from Invitrogen
  FBS                                                       Cell culture           CellGro              10437-028         Original cat \# unspecified
  OPTI-MEM                                                  Cell culture           Life Technologies    31986070          Original unspecified
  0.45 µm low binding syringe filter                        Labware                Millipore            SLHV013SL         Original unspecified
  Endo-free maxiprep kit                                    Kit                    Qiagen               12362             Original unspecified
  Protein Concentration Assay; Quick Start Bradford Assay   Reporter assay         Bio-Rad              500-0205          Original unspecified
  Spectrophotometer                                         Instrument             Beckman Coulter      DU800             Original unspecified
  TRIzol                                                    Chemical               Invitrogen           15596-018         Original cat\# unspecified
  SuperScript II reverse transcriptase                      Kit                    Invitrogen           18064-014         Original cat\# unspecified
  7900HT Sequence Detection System                          Instrument             Applied Biosystems                     
  Pparg Taqman assays; Hs00234592_m1                        Nucleic acid           Applied Biosystems   Cat. \# 4351372   Original assay unspecified
  Cebpa Taqman assays; Hs00269972_s1                        Nucleic acid           Applied Biosystems   Cat. \# 4331182   Original assay unspecified
  Adipoq Taqman assays; Hs00605917_m1                       Nucleic acid           Applied Biosystems   Cat. \# 4331182   Original assay unspecified
  18S rRNA Taqman assays; Hs99999901_s1                     Nucleic acid           Applied Biosystems   Cat. \# 4331182   Original assay unspecified

### Procedure {#s2-2-3}

Note: 3T3-L1 and 293T cells are maintained in DMEM with 10% FBS at 37°C/5% CO~2 .~All cells will be sent for STR profiling and mycoplasma testing. pLPC (empty vector), pLPC-*IDH2*, and pLPC-*IDH2*^R172K^ are generated in Protocol 1.

-   Generate vector and *IDH2* wild type and mutant expressing retroviruses.^\#^Transfect 293T cells with pCL-Eco helper plasmid and vector or *IDH2* vectors.Spot virus construct in 6 well plates at 1000 ng/well.Perform X-tremeGeneHP reverse transfection as follows:Make the helper plasmid mix; 700 ng/well.Add 4 µL of XtremeGene HP to 400 µL OPTI-MEM.Mix by light tapping.Mix together the helper plasmids with the XtremeGeneHP reagent and OPTI-MEM.Add 400 µL of the mix to each well and incubate for at least 30 min at room temperature.Meanwhile, resuspend 293T cells in DMEM + 10% FBS at 1.2x10^6^ cells/ml.Add 1600 µL of cells to each well.^\#^24 hr later, replace media (2 ml total).^\#^48 hr post transfection, collect supernatant from each well.Centrifuge at 500x*g* for 10 min at room temperature to pellet debris.Filter supernatant through a 0.45 µm syringe filter, aliquot and store at -80°C.

-   Transduce 3T3-L1 cells with viral supernatant.^\#^Seed cells in 6-well plates and incubate overnight.Cells should be 50-60% confluent the next day.^\#^Add viral supernatant to medium.Supernatant will be added at varying concentrations to determine optimal transduction efficiency; 1:5 to 1:10 -- 150 to 300 µL per well.^\#^Adjust media volume to 1.4 ml per well.^\#^Add polybrene in 100 µL of media into each well for a final concentration of 8 µg/ml.^\#^Spinoculate by spinning at 1000x*g* for 60 min at room temperature.Incubate overnight.^\#^Change media to remove viral transduction media.Replace with fresh media.Grow cells with 2.5 µg/ml puromycin for 7 days to select for stable expression of either wild-type or mutant *IDH2*.Maintain cells in puromycin.Also treat a non-transduced well of 3T3-L1 cells as a control showing susceptibility to puromycin.Split each biological replicate into 5 plates for the four assays being performed.Plate 1 is for Western blotPlate 2 is for GC-MSPlate 3 is for Oil-Red-O staining (harvested 7 days after differentiation)Plate 4 and 5 are for qRT-PCR (harvested 0 and 4 days after differentiation)

-   Generate whole cell lysates from the first plate of each cohort:Lyse cells and sonicate in RIPA buffer.RIPA buffer: 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100, 0.01 M Tris pH 8.0 and 0.14 M NaCl^\#^Sonicate for 1 min, at 180 watts with rounds of 10 sec on/10 sec off. Keep sample on ice during sonication.Centrifuge lysates at 14000x*g* for 10 min at 4°C.Collect supernatant and measure total protein concentration ^\#^using a Bradford assay.Perform Western blot as outlined in Protocol 1 Step 6 using the following primary antibodies ^\*^at the manufacturer's recommended dilution:Anti-IDH1Anti-IDH2

-   Harvest the second plate for metabolite analysis by mass spectrometry as described in Protocol 1 Step 4.

-   Induce 3T3-L1 cells to differentiate into adipocytes.Incubate cells for 2 days with a differentiation cocktail composed of 0.5 mM isobutylmethylxanthine, 1 mM dexamethasone, 5 mg/ml insulin and 5 mM troglitazone supplementing the standard media.After 3 days, maintain cells with 5 mg/ml insulin until harvested.

-   After 7 days of differentiation, assess adipogenesis by Oil-Red-O staining in the third plate from each cohort.Wash cells in PBS and fix in 3% paraformaldehyde for 20 min at room temperature.Wash cells with de-ionized water.Stain with Oil-Red-O solution according to the manufacturer's protocol.Image stained wells by brightfield microscopy and ^\*^quantify Oil-Red-O staining by extracting oil-red-o in isopropanol and reading absorbance at 500 nm.

-   Harvest fourth plate for RNA extraction at Day 0 of differentiation and the fifth plate at Day 4 of differentiation and perform qRT-PCR to assess expression levels of adipocyte markers at each time point.Harvest cells and extract RNA using TRIzol according to the manufacturer's instructions.Reverse transcribe RNA and synthesize cDNA using SuperScript II reverse transcriptase according to the manufacturer's protocol.Assess purity and concentration of RNA and cDNA spectrophotometrically; record A~260~/A~280~ and A~260~/A~230~ ratios.Perform qPCR on a 7900HT Sequence Detection system using Taqman gene expression assays for the following genes:PpargCebpaAdipoq18S rRNA for normalization.^\*^Primers sequences and PCR cycling conditions will be optimized.

-   Repeat independently from Step 2 onwards an additional four times.

### Deliverables {#s2-2-4}

-   Data to be collected:Whole gel images of Western blots with ladder (as seen in Figure 2A)^\*^Densitometric quantification of bandsAlso normalized to the loading control.Images of wells stained with Oil-Red-O (as seen in Figure 2B)^\*^Quantification of Oil-Red-O levels for each cohortAll raw qRT-PCR dataGraph of gene expression over time for each of the three adipocyte markers (as seen in Figure 2D)

### Confirmatory analysis plan {#s2-2-5}

-   Statistical Analysis of the Replication Data: Note: At the time of analysis we will calculate Pearson's *r* to check for correlation between the three dependent variables, normalized gene expression for each of the adipocyte markers, for the qRT-PCR data. We will also perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the qRT-PCR data and 2HG/glutamate ratios. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed we will perform a log transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test listed in Power Calculations for this protocol.Western Blot:Confirmatory; no analysis performed2HG/glutamate ratio:One-way ANOVA (one dependent variable is the 2HG/glutamate ratio; three independent variables are the vector and *IDH2* variants) with the following planned comparison using Fisher's LSD correction:*IDH2*^R172K^compared to *IDH2*^WT^qRT-PCR:One-way MANOVA (three dependent variables are the normalized gene expression of each of the adipocyte markers on day 4; three independent variables are the vector and IDH2 variants) with the following planned comparisons using Bonferroni's correction:*IDH2*^R172^compared to vector for each gene (three comparisons total)*IDH2*^R172K^compared to *IDH2*^WT^ for each gene (three comparisons total)

-   Meta-analysis of original and replication attempt effect sizes:For qRT-PCR:The replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.For 2HG/glutamate ratios:The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the representative image, as a single point on the same plot for comparison.

-   Additional exploratory analysis:Oil-Red-O staining:One-way ANOVA (one dependent variable is the A~500~ readings; three independent variables are the vector and *IDH2* variants) with the following planned comparison using Fisher's LSD correction:*IDH2*^R172K^ compared to *IDH2*^WT^

### Known differences from the original study {#s2-2-6}

-   Aspects of the Western blot protocol are provided by the replicating lab; complete details of the original protocol were unavailable.

-   Aspects of the viral production protocol are adapted from the replicating lab's in-house protocol.Viral supernatant will be collected only at 48 hr post-transection and will not be combined with viral supernatant collected at 72 hr.

-   In addition to imaging Oil-Red-O stained plates, the replication attempt will quantify the amount of Oil-Red-O staining spectrophotometrically.

### Provisions for quality control {#s2-2-7}

All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/vfsbo/>).

-   Sequence files and agarose gel images confirming vector identity and integrity

-   Ponceau stains confirming protein transfer to membranes

-   STR profiling and mycoplasma testing results

-   Absorbance data for RNA and cDNA

Protocol 3: Assessing the role of KDM4C on differentiation of 3T3-L1 cells {#s2-3}
--------------------------------------------------------------------------

This protocol describes how to treat 3T3-L1 cells with an siRNA against the histone demethylase KDM4C, whose activity is inhibited by 2HG, and assess the effect of loss of KDM4C activity on methylation and differentiation, as seen in Figure 4D and Supplemental Figure 8.

### Sampling {#s2-3-1}

-   This experiment will be repeated 3 times for a minimum power of 80%. The Western blot data is qualitative, thus to determine an appropriate number of replicates to initially perform, sample sizes based on a range of potential variance was determined.See Power calculations for details.

-   Each experiment consists of five cohorts:Cohort 1: 3T3-L1 cells treated with scramble control siRNAsCohort 2: 3T3-L1 cells treated with siRNAs \#1 against KDM4CCohort 3: 3T3-L1 cells treated with siRNAs \#2 against KDM4CCohort 4: 3T3-L1 cells treated with siRNAs \#3 against KDM4CCohort 5: untreated 3T3-L1 cells \[additional control\]

-   Each cohort is induced to differentiate, followed by:Assessment of methylation by Western blot for:Anti-KDM4CAnti-H3K9me3Anti-H3Anti-β-actinAssessment of differentiation by Oil-Red-O staining

### Materials and reagents {#s2-3-2}

  Reagent                                 Type                   Manufacturer                                              Catalog \#       Comments
  --------------------------------------- ---------------------- --------------------------------------------------------- ---------------- -----------------------------------
  3T3-L1 cells                            Cell line              ATCC                                                      CL-173           Original source unspecified
  DMEM                                    Cell culture           Corning                                                   15013 CV         Replaces original from Invitrogen
  FBS                                     Cell culture           CellGro                                                   10437-028        Original cat \# unspecified
  KDM4C siRNA \#1                         Nucleic acid           Synthesis left to the discretion of the replicating lab                    
  KDM4C siRNA \#2                         Nucleic acid           Synthesis left to the discretion of the replicating lab                    
  KDM4C siRNA \#3                         Nucleic acid           Synthesis left to the discretion of the replicating lab                    
  Scrambled control siRNA                 Nucleic acid           Dharmacon                                                 D-001810-01-20   
  Lipofectamine RNAiMAX                   Cell culture           Invitrogen                                                13778-030        Original cat\# unspecified
  isobutylmethylxanthine                  Inhibitor              Sigma                                                     I5879            Original cat\# unspecified
  dexamethasone                           Chemical               Sigma                                                     D4902            Original cat\# unspecified
  insulin                                 Growth factor          Sigma                                                     I3536            Original cat\# unspecified
  Troglitazone                            Chemical               Sigma                                                     T2573            Original cat\# unspecified
  RIPA buffer                             Cell culture           Millipore                                                 20188            Original source unspecified
  Nitrocellulose membrane                 Western blot reagent   Life Technologies                                         LC2006           Original source unspecified
  Ponceau stain                           Chemical               Sigma                                                     P7170            Original unspecified
  Mouse IgG~2a~ monoclonal anti-β-actin   Antibody               Sigma                                                     A5316            
  Rabbit IgG monoclonal anti-H3           Antibody               Cell Signaling Technology                                 4499             
  Rabbit polyclonal anti-H3K9me3          Antibody               Abcam                                                     Ab8898           
  Rabbit polyclonal anti-KDM4C            Antibody               Abcam                                                     Ab85454          
  Oil-Red-O                               Chemical               Sigma                                                     O1391            Original source unspecified
  paraformaldehyde                        Chemical               Tousimis                                                  1008A            Original source unspecified

### Procedure {#s2-3-3}

Note: 3T3-L1 cells are maintained in DMEM with 10% FBS at 37°C/5% CO~2~.~ ~All cells will be sent for STR profiling and mycoplasma testing.

-   Transfect with 3T3-L1 cells with siRNAs against KDM4C:Plate out equal densities of single cell suspensions of 3T3-L1 cells in ^\#^6-well plates.^\*^Optimize the number of cells to plate per well.Plate out two plates per siRNA pool (control vs. siKDM4C).One will be harvested on Day 3 of differentiation for Western blot analysis.One will be used on Day 7 of differentiation for Oil-Red-O analysis.Transfect with the following siRNAs at a final concentration of 40 nM using Lipofectamine RNAiMAX according to the manufacturer's instructions.1Sense5'-GCUUGAAUCUCCCAAGAUATT-3'Antisense5'-UAUCUU GGGAGAUUCAAGCTT-3'2Sense5'-CAAAGUAUCUUGGAUCAAATT-3'Antisense5'-UUUGAUCCAAGAUACUUUGCC-3'3Sense5'-GAGGAGUU UCGGGAGUUCAACAAAU-3'Antisense5'-AUUUGUUGAACUCCCGAA ACUCCUC-3'Transfect control wells with a scrambled control siRNA.Also plate control wells with no transfection.Incubate for 3 days.

-   Induce differentiation of control siRNA and antisense siRNA transduced 3T3-L1 cells as specified in Protocol 2 Step 6.

-   3 days after differentiation, harvest one plate from each treatment and prepare whole cell lysates as specified in Protocol 2 Step 7.

-   Perform Western blot analysis on all whole cell lysates from Day 3 as described in Protocol 2 Step 7.Probe with:Anti-KDM4CAnti-H3K9me3Anti-H3Anti-β-actinQuantify band intensities with ImageJ.Normalize H3K9me3 band intensities to total H3.Normalize KDM4C band intensities to ß-actin.

-   At Day 7 of differentiation, assess level of differentiation by Oil-Red-O staining as specified in Protocol 2 Step 8.Image wells and quantify Oil-Red-O expression.

-   Repeat experiment an additional two times.

### Deliverables {#s2-3-4}

-   Data to be collected:Whole gel images of all Western blots with ladder (as seen in the top of Figure 4D)Images of Oil-Red-O stained wells (as seen in the bottom half of Figure 4D)

-   Quantification of Oil-Red-O staining at Day 7 of differentiation (compare to Supplemental Figure 8B)

### Confirmatory analysis plan {#s2-3-5}

-   Statistical Analysis of the Replication Data: Note: At the time of analysis we will calculate Pearson's *r* to check for correlation between the two dependent variables, normalized intensities measured for KDM4C and H3K9me3, for the Western blot data. We will also perform the Shapiro-Wilk test and generate a quantile-quantile plot to assess the normality of the Western blot and Oil-Red-O data. We will also perform Levene's test to assess homoscedasticity. If the data appears skewed we will perform a log transformation in order to proceed with the proposed statistical analysis. If this is not possible we will perform the equivalent non-parametric test listed in Power Calculations for this protocol.Quantification of Oil-Red-O staining:One way ANOVA (one dependent variable is the A~500~ readings; four independent variables are the control and three KDM4C siRNA sequences) with the following planned comparisons using Bonferroni's correction:Control siRNA compared to KDM4C siRNA \#1Control siRNA compared to KDM4C siRNA \#2Control siRNA compared to KDM4C siRNA \#3 \[additional exploratory analysis\]Western blot:One-way MANOVA (two dependent variables are the normalized intensities measured for KDM4C and H3K9me3; four independent variables are the control and three KDM4C siRNA sequences) with the following planned comparisons using Bonferroni's correction:H3K9me3 levels:Control siRNA compared to KDM4C siRNA \#1Control siRNA compared to KDM4C siRNA \#2Control siRNA compared to KDM4C siRNA \#3KDM4C levels (QC):Control siRNA compared to KDM4C siRNA \#1Control siRNA compared to KDM4C siRNA \#2Control siRNA compared to KDM4C siRNA \#3

-   Meta-analysis of original and replication attempt effect sizes:Oil-Red-O staining for siRNA \#1 and \#2:This replication attempt will perform the statistical analysis listed above, compute the effects sizes, compare them against the reported effect size in the original paper and use a meta-analytic approach to combine the original and replication effects, which will be presented as a forest plot.There is no originally reported data from siRNA \#3, therefore it will not be included.Western Blot:The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the representative image, as a single point on the same plot for comparison.

### Known differences from the original study {#s2-3-6}

1.  The replication will perform the Oil-Red-O quantification for all three siRNAs, not just \#1 and \#2 as presented in Supplemental Figure 8.

### Provisions for quality control {#s2-3-7}

All data obtained from the experiment - raw data, data analysis, control data and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<https://osf.io/vfsbo/>).

-   Ponceau stains confirming protein transfer to membranes

-   STR profiling and mycoplasma testing results

### Power calculations {#s2-3-8}

Note: details of all power calculations can be found at [https://osf.io/rb32p/](https://osf.io/rb32p/?view_only=9044639bba8b4f03af6ea1b8454e8bb1)

Protocol 1 {#s2-4}
----------

### Summary of original data {#s2-4-1}

Note: data estimated from published figures.

Supplemental Figure 1: normalized WB band intensity (normalized to Vector)MeanSDNIDH1^WT^H3K9me21.70.83H3K9me310.23K3K4me31.20.63H3K27me30.40.33H3K36me31.20.43H3K27me20.80.43IDH1^R132H^H3K9me27.92.53H3K9me34.11.23K3K4me33.40.83H3K27me32.50.53H3K36me31.70.83H3K27me24.72.53IDH2^WT^H3K9me23.21.13H3K9me32.11.23K3K4me31.90.33H3K27me31.90.83H3K36me31.40.43H3K27me21.50.93IDH2^R172K^H3K9me211.43.83H3K9me34.91.63K3K4me341.43H3K27me33.61.63H3K36me31.80.73H3K27me25.43.73

Figure 1B: 2HG/glutamate ratiosMeanAssumed NIDH1^WT^0.0053IDH1^R132H^0.0523IDH2^WT^0.0233IDH2^R172K^1.563

### Test family {#s2-4-2}

-   Western blot; Figure 1B/Supplemental Figure 1A: Note: Since we do not have the raw data, we were unable to perform power calculations using a MANOVA. We are approximating sample sizes with corrected one-way ANOVAs for each DV (normalized histone methylations).Bonferroni-corrected one-way ANOVAs (one per DV) followed by Bonferroni corrected planned comparisons:Wild-type IDH1 compared to IDH1^R132H^, collapsed across all histone lysine methylations.Wild-type IDH2 compared to IDH2^R172K^, collapsed across all histone lysine methylations.Note: Only H3K9me2 is being included since this is the histone modification with the largest effect size reported. A correlation among all the histone methylations will also be performed prior to performing the proposed analysis plan.

-   2HG/glutamate ratios; Figure 1B:One-way ANOVA followed by Bonferroni-corrected pairwise comparisons for the following:IDH1^WT^ compared to IDH1^R132H^, for H3K9me2IDH2^WT^ compared to IDH2^R172K^, for H3K9me2

### Power calculations {#s2-4-3}

-   Power calculations were performed using R software (version 3.2.2) (R [@bib2]) and G\*Power (version 3.1.7) ([@bib5])

-   Partial η^2^ calculated as in [@bib9]

-   Western blot calculations:Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA a Kruskal-Wallis would be performed as the non-parametric alternative, which would require an \~15% increase in sample size calculated for the parametric test listed.

One-way ANOVA: α=0.00833, 4 groupsαDVF(3,8)Partial η2Effect size *f*A priori powerTotal Sample SizeH3K9me210.4860.797261.9830292.1%^1^12^1^H3K9me37.02740.724921.6233596.4%^1^16^1^H3K4me36.61970.712841.5755695.1%^1^16^1^H3K27me36.03390.693511.5042392.7%^1^16^1^H3K36me30.62760.190511.0612590.2%24H3K79me23.00330.529691.07984^2^80.0%^2^24[^1][^2]

Planned contrasts; two-tailed *t*-test: α=0.004167Group 1Group 2Effect size *d*A priori powern/groupIDH1^WT^IDH1^R132H^3.3403984.9%^1^5^1^IDH2^WT^IDH2^R172K^2.9313887.3%6Planned contrasts; two-tailed Wilcoxon-Mann-Whitney: α=0.025Group 1Group 2Effect size *d*A priori powern/groupIDH1^WT^IDH1^R132H^3.3403980.9%^2^5^2^IDH2^WT^IDH2^R172K^2.9313884.0%6[^3][^4]

-   2HG/glutamate ratio calculations:Note: The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.

2%; one-way ANOVA: α=0.05, 4 groupsF(3,8)Partial η^2^Effect size *f*A priori powerTotal Sample Size7240.70.9996352.1190199.9%8Planned comparisons; 2-tailed *t*-test: α=0.025Group 1 versusGroup 2Effect size *d*A priori powern per groupIDH1^WT^IDH1^R132H^63.618299.9%2IDH2^WT^IDH2^R172H^69.660699.9%2

15%; one-way ANOVA: α=0.05, 4 groupsF(3,8)Partial η^2^Effect size *f*A priori powerTotal Sample Size128.720.979706.9477299.9%8Planned comparisons; 2-tailed *t*-test: α=0.025Group 1 versusGroup 2Effect size *d*A priori powern per groupIDH1^WT^IDH1^R132H^8.4824283.5%2IDH2^WT^IDH2^R172H^9.2880888.4%2

28%; one-way ANOVA: α=0.05, 4 groupsF(3,8)Partial η2Effect size *f*A priori powerTotal Sample Size36.9420.932683.7220199.9%8Planned comparisons; 2-tailed *t*-test: α=0.025Group 1 versusGroup 2Effect size *d*A priori powern per groupIDH1^WT^IDH1^R132H^4.5441592.4%3IDH2^WT^IDH2^R172H^4.9757695.9%3

40%; one-way ANOVA: α=0.05, 4 groupsF(3,8)Partial η2Effect size *f*A priori powerTotal Sample Size18.1020.871602.6054296.0%8Planned comparisons; 2-tailed *t*-test: α=0.025Group 1 versusGroup 2Effect size *d*A priori powern per groupIDH1^WT^IDH1^R132H^3.1809189.6%4IDH2^WT^IDH2^R172H^3.4830394.2%4

In order to produce quantitative replication data, we will run the experiment six times. Each time we will quantify the 2HG/glutamate ratio. We will determine the standard deviation across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.

Protocol 2 {#s2-5}
----------

### Summary of original data {#s2-5-1}

Note: data estimated from published figures.

Figure 2A: 2HG/glutamate ratioAssumed NMeanVector0.13IDH1^R172K^5.33IDH2^WT^0.13

Figure 2D: Relative expression of adipocyte markersPpargMeanSDNVectorDay 01.450.8233Day 413.9920.8163*IDH2*^WT^Day 02.5211.0763Day 410.9660.8793*IDH2*^R172K^Day 01.1340.8233Day 44.2230.9413CebpaMeanSDNVectorDay 01.1230.4213Day 43.0531.1883*IDH2*^WT^Day 01.930.4563Day 44.8070.5653*IDH2*^R172K^Day 00.6670.4913Day 40.2460.213AdipoqMeanSDNVectorDay 0058.6213Day 4572.414193.1033*IDH2*^WT^Day 0058.6213Day 4448.27686.2073*IDH2*^R172K^Day 0058.6213Day 441.37927.5863

### Test family {#s2-5-2}

-   2HG/glutamate ratios; Figure 2A bottom:One way ANOVA followed by Fisher's LSD for the following comparison:IDH2^WT^ vs. IDH2^R172K^

-   qRT-PCR; Figure 2D: Note: Since we did not have the raw data, we were unable to perform power calculations using a MANOVA. We are approximating the sample sizes with corrected one-way ANOVAs for each DV (gene).Bonferroni-corrected one-way ANOVAs (one per gene) followed by Bonferroni corrected comparisons for Day 4 timepoints:*IDH2*^R172K^compared to vector for each gene (3 comparisons total)*IDH2*^R172K^compared to *IDH2*^WT^ for each gene (3 comparisons total)

### Power calculations {#s2-5-3}

-   Power calculations were performed using R software (version 3.2.2) (R [@bib2]) and G\*Power (version 3.1.7) ([@bib5])

-   Partial η^2^ calculated as in [@bib9]

-   2HG/glutamate ratios:Note: The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.

2%; one-way ANOVA: α=0.05, 3 groupsF(2,6)Partial η^2^Effect size *f*A priori powerTotal Sample Size7214.50.9995849.018899.9%6Planned comparisons; two-tailed *t-*test: α=0.05Group 1 versusGroup 2Effect size *d*A priori powern per groupIDH2^R172H^IDH2^WT^84.938399.9%2

15%; one-way ANOVA: α=0.05, 3 groupsF(2,6)Partial η2Effect size *f*A priori powerTotal Sample Size128.260.977156.5386699.9%6Planned comparisons; two-tailed *t*-test: α=0.05Group 1 versusGroup 2Effect size *d*A priori powern per groupIDH2^R172H^IDH2^WT^11.325299.8%2

28%; one-way ANOVA: α=0.05, 3 groupsF(2,6)Partial η2Effect size *f*A priori powerTotal Sample Size36.8090.924643.5028598.5%6Planned comparisons; two-tailed *t*-test: α=0.05Group 1 versusGroup 2Effect size *d*A priori powern per groupIDH2^R172H^IDH2^WT^6.0670484.2%2

40%; one-way ANOVA: α=0.05, 3 groupsF(2,6)Partial η2Effect size *f*A priori powerTotal Sample Size18.0360.857392.4519485.1%6Planned comparisons; two-tailed *t*-test: α=0.05Group 1 versusGroup 2Effect size *d*A priori powern per groupIDH2^R172H^IDH2^WT^4.2468896.6%3

In order to produce quantitative replication data, we will run the experiment five times. Each time we will quantify the 2HG/glutamate ratio. We will determine the standard deviation across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.

-   qRT-PCR:Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA a Kruskal-Wallis would be performed as the non-parametric alternative, which would require an \~15% increase in sample size calculated for the parametric test listed.

PpargOne-way ANOVA: α=0.0167, 3 groupsF(2,6)Partial η^2^Effect size *f*A priori powerTotal Sample Size96.8540.969965.6819599.5%^1^6^1^Planned comparisons; two-tailed *t*-test: α=0.0083Group 1 versusGroup 2Effect size *d*A priori powern per group*IDH2*^R172H^Vector11.092199.9%^2^3^2^*IDH2*^R172H^*IDH2*^WT^7.4055998.6%^2^3^2^Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: α=0.0083Group 1 versusGroup 2Effect size *d*A priori powern per group*IDH2*^R172H^Vector11.092199.9%^2^3^2^*IDH2*^R172H^*IDH2*^WT^7.4055996.9%^2^3^2^[^5][^6]

CebpaOne-way ANOVA: α=0.0167, 3 groupsF(2,6)Partial η^2^Effect size *f*A priori powerTotal Sample Size26.8430.899475.6819590.5%^1^6^1^Planned comparisons; two-tailed *t*-test: α=0.0083Group 1 versusGroup 2Effect sizeA priori powern per group*IDH2*^R172H^Vector3.2904891.6%5*IDH2*^R172H^*IDH2*^WT^10.701199.9%^2^3^2^Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: α=0.0083Group 1 versusGroup 2Effect size *d*A priori powern per group*IDH2*^R172H^Vector3.2904889.0%5*IDH2*^R172H^*IDH2*^WT^10.701199.9%^2^3^2^[^7][^8]

AdipoqOne-way ANOVA: α=0.0167, 3 groupsF(2,6)Partial η^2^Effect size *f*A priori powerTotal Sample Size15.2690.835792.2560396.3%^1^9^1^Planned comparisons; two-tailed *t*-test: α=0.0083Group 1 versusGroup 2Effect sizeA priori powern per group*IDH2*^R172H^Vector3.8500187.8%^2^4^2^*IDH2*^R172H^*IDH2*^WT^6.3575294.5%^3^3^3^Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: α=0.0083Group 1 versusGroup 2Effect size *d*A priori powern per group*IDH2*^R172H^Vector3.8500184.0%^4^4^4^*IDH2*^R172H^*IDH2*^WT^6.3575290.8%^3^3^3^[^9][^10][^11][^12][^13]

Protocol 3 {#s2-6}
----------

### Summary of original data {#s2-6-1}

Note: data estimated from published figures.

Figure 4D and S8A: Western BlotBand intensity (normalized to H3)KDM4CControl siRNA1*KDM4C* siRNA \#10.5097^1^*KDM4C* siRNA \#20.2767^1^*KDM4C* siRNA \#30.0249^2^H3K9me3Control siRNA1*KDM4C* siRNA0.3695^2^[^14][^15]

Supplemental Figure 8B: Oil-Red-O quantificationMeanSDNControl1.060.033siRNA \#10.420.153siRNA \#20.690.093siRNA \#3^1^0.690.093[^16]

### Test family {#s2-6-2}

-   Western blot; Figure 4D and S8A: Note: Since we did not have the raw data, we were unable to perform power calculations using a MANOVA. We are approximating the sample sizes with corrected one-way ANOVAs for each DV (normalized protein).One-way ANOVAs followed by Bonferroni corrected comparisons:H3K9me3 levels in control siRNA compared to each *KDM4C* siRNA (3 comparisons total)*KDM4C* levels in control siRNA compared to each KDM4C siRNA (3 comparisons total)

-   Quantification of Oil-Red-O staining; Figure S8B:One way ANOVA followed by Bonferroni corrected comparisons:Control siRNA compared to *KDM4C* siRNA \#1Control siRNA compared to *KDM4C* siRNA \#2Control siRNA compared to *KDM4C* siRNA \#3

### Power calculations {#s2-6-3}

-   Power calculations were performed using R software (version 3.2.2) (R [@bib2]) and G\*Power (version 3.1.7) ([@bib5]).

-   Partial η^2^ calculated as in [@bib9].

-   Western BlotNote: The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance.

2%; One-way ANOVA: α=0.025, 4 groups αDVF(3,8)Partial η^2^Effect size *f*PowerTotal sample sizeH3K9me32114.70.9987428.16199.9%8*KDM4C*3865.50.9993138.07399.9%8Planned comparisons; two-tailed *t*-test: α=0.0083DVGroup 1 versusGroup 2Effect size *d*A priori powern per groupH3K9me3ControlKDM4C \#153.09999.9%2ControlKDM4C \#253.09999.9%2ControlKDM4C \#353.09999.9%2KDM4CControlKDM4C \#142.40799.9%2ControlKDM4C \#262.55299.9%2ControlKDM4C \#384.33599.9%2

15%; One-way ANOVA: α=0.025, 4 groupsDVF(3,8)Partial η^2^Effect size *f*PowerTotal sample sizeH3K9me337.5950.933773.754799.2%8KDM4C68.720.962645.076499.9%8Planned comparisons; two-tailed *t*-test: α=0.0083DVGroup 1 versusGroup 2Effect size *d*A priori powern per groupH3K9me3ControlKDM4C \#17.080097.8%3ControlKDM4C \#27.080097.8%3ControlKDM4C \#37.080097.8%3KDM4CControlKDM4C \#15.654388.5%3ControlKDM4C \#28.340399.6%3ControlKDM4C \#311.24599.9%3

28%; One-way ANOVA: α=0.025, 4 groupsDVF(3,8)Partial η^2^Effect size *f*PowerTotal sample sizeH3K9me310.7890.801822.011498.7%12KDM4C19.7220.880892.719589.2%8Planned comparisons; two-tailed *t*-test: α=0.0083DVGroup 1 versusGroup 2Effect size *d*A priori powern per groupH3K9me3ControlKDM4C \#13.792886.8%4ControlKDM4C \#23.792886.8%4ControlKDM4C \#33.792886.8%4KDM4CControlKDM4C \#13.029185.9%5ControlKDM4C \#24.468095.8%4ControlKDM4C \#36.024092.1%3

40%; One-way ANOVA: α=0.025, 4 groupsDVF(3,8)Partial η^2^Effect size *f*PowerTotal sample sizeH3K9me35.28680.664721.408080.2%12KDM4C9.66370.783731.903797.6%12Planned comparisons; two-tailed *t*-test: α=0.0083DVGroup 1 versusGroup 2Effect size *d*A priori powern per groupH3K9me3ControlKDM4C \#12.655087.2%6ControlKDM4C \#22.655087.2%6ControlKDM4C \#32.655087.2%6KDM4CControlKDM4C \#12.120485.6%8ControlKDM4C \#23.127688.3%5ControlKDM4C \#34.216893.3%4

In order to produce quantitative replication data, we will run the experiment three times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.

-   Oil-Red-O staining:Note: Due to the large variance, these parametric tests are only used for comparison purposes. The sample size is based on the non-parametric tests also listed. For the ANOVA a Kruskal-Wallis would be performed as the non-parametric alternative, which would require an \~15% increase in sample size calculated for the parametric test listed.

One-way ANOVA: α=0.05, 4 groupsF(3,8)Partial eta^2^Effect size *f*PowerTotal Sample Size20.9390.887032.802297.8%^1^8^1^[^17]

Planned comparisons; two-tailed Wilcoxon-Mann-Whitney: α=0.0167Power CalculationsGroup 1Group 2Effect size *d*Powern/groupControlKDM4C \#15.916896.9%3ControlKDM4C \#25.515693.3%3ControlKDM4C \#35.515693.3%3Planned comparisons; two-tailed *t*-test: α=0.0167Group 1Group 2Effect size *d*Powern/groupControlKDM4C \#15.916897.7%3ControlKDM4C \#25.515695.6%3ControlKDM4C \#35.515695.6%3
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"Registered report: IDH mutation impairs histone demethylation and results in a block to cell differentiation\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Irwin Davidson (Reviewing Editor) and Randy Schekman (Senior Editor).

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

The reviewers found this proposed study to have important impact on the functional consequences of the frequently occurring IDH mutations and their mode of action. The provided protocol appears complete, but several points concerning the statistical methods remain to be clarified.

Essential revisions:

Normality and homoscedasticity will be assessed using adequate tests and methods. However what kind of transformation do the authors plan to apply in case of skewed data? Do the authors have an idea of how the data could be skewed? Similarly, which test do the authors intend to apply in case of non-normal data?

Power calculations assume normally distributed data. In the opposite case non parametric tests will be used with much less power. Power calculations should be taken with caution, as they are performed according to an optimistic scenario.

Protocol 1:

The authors should clarify if the MANOVA analyses are planned to analyze the results of western blots and that:

a\) Response variables are intensities measured for H3K9me2, H3K9me3, etc.;b) The factor of variability is the cohort with 5 different levels: control, IDH1^-WT^, IDH1 mutant, IDH2^-WT^, IDH2 mutant;c) Contrasts to be tested are the ones listed under the subsection "Confirmatory analysis plan" (H3K9me2, WT vs. mutant, etc.).

Clarifications should be made for each model used in this protocol, as it is not always clear how the suggested model fits the data. The same comments hold true for the other protocols, for example the 2HG/glutamate ratios where there is only one response variable and a factor of variability with 5 levels with 2 tested contrasts.

Protocol 2:

For the 2HG/glutamate ratio, please describe the model (one factor with three levels, one contrast?).

For the qRT-PCR, is it a per-gene model? What are the response variables? Please clarify.

Protocol 3:

Again please clarify the MANOVA model (response variable, factor levels, contrasts).

10.7554/eLife.10860.003

Author response

Essential revisions: Normality and homoscedasticity will be assessed using adequate tests and methods. However what kind of transformation do the authors plan to apply in case of skewed data? Do the authors have an idea of how the data could be skewed? Similarly, which test do the authors intend to apply in case of non-normal data?

We have included the potential of a logarithmic transformation in case of skewed data in the revised manuscript. This might be the case with the 2HG/glutamate ratios that are listed in the protocols, which only show representative images, but display them on a log scale, which suggests the data might be skewed.

In the case of non-normal data, the revised manuscript includes the non-parametric tests that would be applied. When there is reason to suspect that a non-parametric test might be applied, such as a large difference in variance between the groups being tested, we have included non-parametric as well as parametric power calculations as described in response to the second question.

*Power calculations assume normally distributed data. In the opposite case non parametric tests will be used with much less power. Power calculations should be taken with caution, as they are performed according to an optimistic scenario.*

We agree and understand the limitations of using the original data we have been able to obtain, or estimate, as a basis for the sample size for the replication attempt. We also agree that some of the assumptions made are according to an optimistic scenario. However, we hope that by performing power calculations using non-parametric tests, when there is reason to believe the data would violate the assumptions of a parametric test, we will ensure the sample size used for the replication study will be suitable for a parametric test (what we aim to perform if possible) or the non-parametric test (what we quite possible will need to perform). Further, as pointed out, this still stands risk of decreased power depending on the nature of the replication data (such as if there is normal distribution) in order to perform the proposed comparisons. Additionally, we have revised the analysis plans and power calculations to reflect the proposed models and contrasts, including the potential non-parametric tests that might be performed.

Protocol 1: The authors should clarify if the MANOVA analyses are planned to analyze the results of western blots and that:

*a) Response variables are intensities measured for H3K9me2, H3K9me3, etc.;b) The factor of variability is the cohort with 5 different levels: control, IDH1^-WT^, IDH1 mutant, IDH2^-WT^, IDH2 mutant;c) Contrasts to be tested are the ones listed under the subsection "Confirmatory analysis plan" (H3K9me2, WT vs. mutant, etc.).*

*Clarifications should be made for each model used in this protocol, as it is not always clear how the suggested model fits the data. The same comments hold true for the other protocols, for example the 2HG/glutamate ratios where there is only one response variable and a factor of variability with 5 levels with 2 tested contrasts. Protocol 2: For the 2HG/glutamate ratio, please describe the model (one factor with three levels, one contrast?).*

For the qRT-PCR, is it a per-gene model? What are the response variables? Please clarify. Protocol 3: Again please clarify the MANOVA model (response variable, factor levels, contrasts).

Thank you for this suggestion. We have included the model of each proposed analysis plan, to reflect the DV, IV, and contrasts proposed. Additionally, we have revised the analysis plans and power calculations to reflect the proposed models and contrasts, included the potential non-parametric tests that might be performed.

[^1]: ^1^ With 6 samples per group (24 total), achieved power is 99.9%.

[^2]: ^2^ Since the original effect size will not be detectable with the proposed sample size, this is the effect size that can be detected at 80% power with the given sample size. The original effect size was 0.48512.

[^3]: ^1^ With 6 samples per group, achieved power is 95.3%.

[^4]: ^2^ With 6 samples per group, achieved power is 93.4%.

[^5]: ^1^ With 5 samples per group (15 total), achieved power is 99.9%.

[^6]: ^2^ With 5 samples per group, achieved power is 99.9%.

[^7]: ^1^ With 5 samples per group (15 total), achieved power is 99.9%.

[^8]: ^2^ With 5 samples per group, achieved power is 99.9%.

[^9]: ^1^ With 5 samples per group (15 total), achieved power is.

[^10]: 99.9%.

[^11]: ^2^ With 5 samples per group, achieved power is 97.9%.

[^12]: ^3^ With 5 samples per group, achieved power is 99.9%.

[^13]: ^4^ With 5 samples per group, achieved power is 96.8%.

[^14]: ^1^ These values were normalized to ß-Actin as seen in Supplemental Figure 8A.

[^15]: ^2^ These values were normalized to total H3 as seen in Figure 4D. Also there is no data for siRNAs \#1 and \#2. We have assumed similar values for siRNA \#3 for the purposes of these calculations.

[^16]: ^1^ There is no data for siRNA \#3. We have assumed similar values as siRNA \#2 for the purposes of these calculations.

[^17]: ^1^ With 3 samples per group (12 total), achieved power is 99.9%.
